K2M Group Holdings Inc (NASDAQ:KTWO) – Stock analysts at William Blair lowered their FY2017 EPS estimates for shares of K2M Group in a report issued on Monday. William Blair analyst K. Krum now forecasts that the medical device company will post earnings per share of ($0.87) for the year, down from their prior estimate of ($0.86). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for K2M Group’s Q1 2018 earnings at ($0.20) EPS, Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.06) EPS and FY2018 earnings at ($0.52) EPS.
KTWO has been the topic of several other reports. Needham & Company LLC dropped their price objective on K2M Group from $27.00 to $26.00 and set a “strong-buy” rating on the stock in a report on Thursday, November 2nd. ValuEngine lowered K2M Group from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. BidaskClub lowered K2M Group from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Oppenheimer reissued a “buy” rating and issued a $24.00 price objective on shares of K2M Group in a report on Friday, November 10th. Finally, Barclays reissued a “buy” rating and issued a $25.00 price objective on shares of K2M Group in a report on Tuesday. Two analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $24.50.
K2M Group (NASDAQ:KTWO) last issued its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The business had revenue of $62.65 million during the quarter, compared to analyst estimates of $62.69 million. During the same period in the previous year, the business posted ($0.19) earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis.
Large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC boosted its stake in shares of K2M Group by 7,765.0% in the third quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock worth $100,000 after acquiring an additional 4,659 shares during the last quarter. Rockefeller Financial Services Inc. purchased a new position in K2M Group during the third quarter worth approximately $105,000. BNP Paribas Arbitrage SA lifted its position in K2M Group by 5,175.3% during the second quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock worth $109,000 after buying an additional 4,399 shares in the last quarter. Dorsey & Whitney Trust CO LLC purchased a new position in K2M Group during the second quarter worth approximately $211,000. Finally, Trexquant Investment LP purchased a new position in K2M Group during the third quarter worth approximately $223,000. 97.95% of the stock is currently owned by hedge funds and other institutional investors.
K2M Group Company Profile
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.